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Objective To examine the role of androgen receptor (AR)
gene amplification and aneusomy of the X chromo-
some in the development of antiandrogen-resistant
prostate cancer.
Patients and methods Twenty patients with prostate
cancer resistant to androgen-deprivation therapy
were selected for study. The records of patients with
tumours before and after antiandrogen therapy, and
with a full clinical follow-up, were retrieved. AR gene
amplification and X chromosome copy number were
assessed by fluorescence in situ hybridization using
a labelled probe at locus Xq11–13 for the AR gene
and a labelled a-satellite probe for the X chromosome.
At least 20 nuclei were scored over three tumour
areas by two independent observers.
Results Aneusomy of the X chromosome was reported
respectively in seven (35%) and 11 (55%) tumours
before and after hormone relapse, the AR gene copy
number was increased in seven (35%) and 13 (65%),
respectively, and AR gene amplification was detected
in one (5%) and three (15%), respectively. Neither
increased AR copy number nor AR amplification in
primary tumours precluded a biological response to
androgen-deprivation therapy.
Conclusion The rate of AR gene amplification is too
low to be solely responsible for the development of
antiandrogen-resistant prostate cancer. Also, the pres-
ence of amplified AR and cells aneusomic for the
X chromosome in primary tumours that respond
to androgen-deprivation therapy suggests that an
increase in AR gene copy number does not prevent
a tumour from responding to this therapy. Therefore
other mechanisms which could cause hormone-
refractory prostate cancer must be investigated
before it is understood why so many patients relapse
with this disease.
Keywords prostate cancer, androgen receptor, X chromo-
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Introduction
The incidence of prostate cancer is higher in men from
the western world than any other cancer and is the
second most frequent cause of male cancer-related deaths
[1–3]. As androgens regulate normal growth and
differentiation of the prostate gland, it is not surprising
that prostate cancer growth is stimulated by androgens
[4]. The effects of androgens on prostate tissue can be
inhibited by androgen receptor (AR) antagonists (anti-
androgens) [5]; 70–80% of men with prostate cancer
treated with antiandrogens respond favourably [6].
However, this effect is transient [7], with most patients
eventually developing androgen-resistant disease [8].
Several theories, e.g. mutation of the AR [7], clonal
expansion of tumour cells hypersensitive to andro-
gens [9] and increased expression of AR [4], have
been proposed as a possible explanation as to why
prostate cancer develops resistance to antiandrogens or
androgen-deprivation therapy. Koivisto et al. [10]
postulated that amplification of the AR gene plays a
key role in progression to refractory prostate cancer
[9,10]. They reported that six of 10 recurrent prostate
tumours resistant to antiandrogens and androgen-
deprivation therapy were polysomic for the X chromo-
some and that three had amplification of the AR gene
[10]. They hypothesized that the combination of these
factors caused the development of prostate cancer
resistant to current first-line therapy, i.e. an increase in
AR protein levels would result in proliferative advan-
tages during antiandrogen therapy [10]. Further studies
with more patients confirmed that polysomy of X
chromosome ranges is detectable in 42–60% of relapsed
tumours from patients with prostate cancer, and
amplification of the AR gene has been reported in
20–30% of recurrent tumours from the same patient
cohorts [9–12].
The largest study to date (339 samples) reported no
AR amplifications in any of the 223 primary tumours
investigated [12]. However, there is still no clearAccepted for publication 6 June 2001
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investigation into AR gene amplification before hormonal
therapy and after the development of antiandrogen
resistance (after hormonal therapy) using paired tumours
from the same patient. In the present pilot study we
investigated AR gene amplification and X chromo-
some status in 42 tumours from 20 patients, all with
paired primary and relapsed (after androgen-deprivation
therapy) tumours from the same patient.
Patients and methods
Twenty patients (mean age at diagnosis 71.1 years,
range 55–83) were retrospectively selected for analysis;
ethical approval was obtained from the local research
and ethical committee for the use of their tissue in the
study. All patients received conventional androgen-
deprivation therapy (orchidectomy or antiandrogens).
Patients were selected for analysis if they initially
responded to treatment (the response being defined by
the PSA level decreasing by at least half ) but sub-
sequently relapsed. PSA values and a full clinical
follow-up were available for each patient. Patients were
classed as having hormone-refractory cancer when
sustained rising PSA levels were recorded and they
were selected for study if a tumour sample was available
after hormone relapse. The initial tumour sample was
either from TURP or TRUS-guided biopsy, but the
relapsed tumour sample was always from TURP, which
was used to treat clinical symptoms.
Sections (5 mm) were cut from archival formalin-fixed,
paraffin-embedded tissue and placed on aminopropyl
triethoxysilane-treated slides. The slides were pretreated
on a VP2000 robotic slide processor (Vysis Ltd, Surrey,
UK). This involved dewaxing and rehydration, pretreat-
ment with 8% sodium thiosulphate at 80uC for 30 min
and digestion with 0.05% pepsin at 37uC for 26 min.
Tissue sections were subsequently post-fixed in 10%
formalin for 10 min and dehydrated through increasing
concentrations of ethanol.
Slides were denatured at 72uC for 2 min; dual-labelling
hybridization with CEP buffer (Vysis) containing X
chromosome a-satellite probe (Spectrum Green@ labelled
CEP X, Vysis) and AR probe (Spectrum Orange@ labelled
probe locus Xq11–13, Vysis) was undertaken at 37uC
overnight on a Misha unit (Shandon, Runcorn, UK).
Slides were then washed in 0.4rsaline-citrate buffer,
0.3% NP-40 at 72uC for 2 min, allowed to air dry and
mounted in 0.5 mg/mL 4,6-diamindino-2 phenylindole-2
hydrochloride in Vectashield antifade (Vetrolabs,
Peterborough, UK). Signals were visualized using a
microscope with a 100 W mercury lamp, with a triple
band-pass filter block specific for the excitation and
emission wavelengths of the Spectrum Green and
Spectrum Orange fluors (Vysis).
Serially sectioned haematoxylin and eosin-stained
tissue sections were first examined microscopically to
locate the tumour areas. Sections stained for fluores-
cence in situ hybridization were then scanned at r100
magnification to locate the tumour areas. Twenty non-
overlapping nuclei per section were evaluated from three
different areas by two independent observers, using a
r100 objective. Signals per nucleus for X chromosome
(green) and AR (orange) were counted on a cell-by-cell
basis and the results recorded manually; cells with no
signals for either X or AR were ignored. The mean
chromosomal copy number for the X chromosome was
calculated by totalling the number of green signals
(X probe) counted in a specific area and dividing by the
number of nuclei assessed. Similarly, the mean gene copy
number of the AR was calculated by totalling the number
of orange signals (AR probe) counted in a specific area and
dividing this by the number of nuclei assessed. Analysis of
copy number in thin tissue sections can be affected by
nuclear truncation [12,13] and we excluded nuclei with
missing signals to ensure that the gene : chromosome
ratio was more accurately represented. Therefore, the
normal range for X chromosome and AR copy number
were identified using the mean chromosomal copy
number from 14 BPH (as a genetically stable control)
samples t3 SD (< 99% CI). Using this approach the
normal range for the AR and chromosome X were
0.91–1.30 and 0.97–1.23, respectively. The AR : X
chromosome ratio in 14 BPH samples was 0.93–1.07
(1.04t3 SD). Amplification was defined as an AR : X ratio
of >1.5 [9]. If tumours were heterogeneous the area
with most abnormalities was used in the final analysis.
Fisher’s exact test was used to compare the level of
X chromosome copy number, AR copy number and AR
gene amplification between primary tumours and those
after hormone deprivation therapy.
Results
Of the 20 patients, two had bone metastases at the time
of initial hormone therapy; 42 tumours were analysed,
including 20 primary tumours and 20 tumours after
relapse; in addition, two patients underwent TURP
during their PSA response and these samples were also
analysed. Of the 20 primary tumours, 11 (55%) had a
Gleason sum of f6, four (20%) a sum of 7 and three
(15%) a sum of o8. The Gleason score was unavail-
able for two primary tumours. The Gleason sum for the
relapsed tumour was always the same or higher than
that of the primary tumour; two patients had a Gleason
sum of 7 (10%) in the relapsed tumour and 18 (90%)
had a Gleason score of o8. One tumour (after hormone
relapse) showed heterogeneity (2.3%). In six cases no
abnormalities of either the X chromosome or AR copy
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number were detected in either the biopsies taken before
or after hormone relapse.
Seven (35%) of the primary tumours and 11 (55%)
relapsed tumours were polysomic for the X chromosome
(Table 1). There was no significant difference in the
number of tumours with aneusomy X before and after
hormone relapse (P=0.2). In two cases the primary
tumours were aneusomic for chromosome X and
normosomic in the relapsed tumour.
Seven (35%) tumours before hormone relapse and 13
(65%) after (P=0.11) had increased copies of the AR
(Table 1). In one case the primary tumour had increased
copies of AR, but only one copy in the relapsed tumour.
Amplification of the AR gene was detected in one (5%)
primary and three (15%) hormone-relapsed tumours
(Table 1); there was therefore no significant difference in
the level of AR gene amplification when primary and
hormone-relapsed tumours were compared (P=0.6).
There was no association between the Gleason sum in the
primary or relapsed tumour and AR amplification. From
the three patients with amplified AR in the hormone-
relapsed tumour, one primary tumour had a Gleason
sum of 9, two a Gleason sum of f6, and two relapsed
tumours had a Gleason sum of o8 and one a Gleason
sum of 7. A further two hormone-relapsed tumours
had high AR : X ratios (1.39 and 1.41), but did not
appear to be amplified (ratio <1.5). From the patients
with amplified hormone-relapsed tumours, two had
undergone orchidectomy and three had received anti-
androgen therapy. Therefore, the type of treatment
received did not appear to influence AR amplification.
Serial PSA levels were used to document the hormonal
response and relapse in all patients (Fig. 1). In patients
where there were no AR abnormalities down-regulation
of PSA by hormonal therapy and subsequent PSA escape
occurred as expected (e.g. Fig. 1a). In the case illus-
trated the biopsy after relapse was obtained following
a 270-fold rise in PSA over 14 months (Fig. 1a). In
the one case with amplification of AR in biopsies both
before and after relapse (Fig. 1b) the PSA level rose from
0.9 mg/L to 1450 mg/L during hormone escape, with no
increase in amplification of AR. Finally, the PSA response
in one of two cases with amplification of AR in the
hormone-relapse biopsy only is shown in Fig. 1c.
Discussion
Hormone-refractory prostate cancer has been postulated
to develop because of amplification of the AR gene [9].
Several studies supporting this hypothesis investigated
levels of AR gene amplifications and aneusomy of
chromosome X in recurrent tumours from patients
who initially responded to androgen-deprivation therapy
[4,9,11,12]. Visakorpi et al. [9] reported that 30% of
recurrent tumour specimens resistant to androgen-
deprivation therapy had AR gene amplification.
Although this level of amplification was too low to be
the sole cause of hormone-refractory prostate cancer, it
was suggested that an increase in AR copy number from
either AR amplification or duplication of the X chromo-
some might be responsible. Visakorpi et al. [9] reported
that a further 35% of tumours investigated were
Table 1 Cases with abnormal X chromosome or AR gene copy number, or an abnormal AR : X chromosome copy number ratio
Patient no.
X chromosome, biopsy AR, biopsy AR : X ratio
before (mid) after relapse before (mid) after relapse before (mid) after relapse
2 1.63 1.58 1.61 1.63
3 1.17 (1.06) 1.41 1.05 (1.07) 1.33
5 1.32 1.46 1.42 1.48
6 1.03 1.68 1.05 2.33 1.02 1.39
7 2.99 (2.72) 1.5 8.68 (11.87) 4.63 2.90 (4.36) 3.09
8 1.03 1.61 1.03 1.61
9 1.46 1.04 1.48 1.04
10 1.13 1.58 1.1 1.48
13 1.07 1.53 1.08 2.15 1.01 1.41
16 1.22 1.79 1.22 1.85
17 1.48 1.43 1.54 1.53
18 1.17 1.25 1.2 1.32
19 1.38 1.1 1.46 2.65 1.06 2.45
20 1.34 1.35 1.31 6.38 1.00 4.90
The mean X chromosome copy number per nucleus is given for each case if either of the biopsies before or after relapse had a mean chromosomal
copy number of o1.3. The mean AR gene copy number per nucleus is given for each case if either of the biopsies before or after relapse had a mean
gene copy number of o1.23. The mean AR : X chromosome ratio is given for each case that had an AR : X chromosome ratio of o1.07, as above this
value is considered abnormal. Cases were considered as having AR amplification if their mean AR : X chromosome ratio was >1.5.
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polysomic for chromosome X. Therefore, 65% of the
recurrent cases investigated had increased AR copy
numbers compared with normal prostate gland cells [9].
These findings have since been confirmed by several
studies reporting amplification of the AR in 20–30% and
polysomy of chromosome X in 35–80% of recurrent
tumours [9,11,12]. These data have been used to suggest
that an increase in AR copy number is involved in the
development of hormone-refractory prostate cancer.
In the present study we have, for the first time,
investigated AR amplification and copy number in paired
tumours before and after hormonal escape in patients
with documented initial responses to antiandrogen
therapy. The results cast doubt on the role of AR
amplification or duplication as mechanisms of hormone
escape. Although 65% of recurrent tumours had an
increase in AR copy number, consistent with values
previously reported [9,11,12], 35% of them also had
increased copies of AR in the pretreatment tumours.
Despite this, each of these patients had a documented
response to antiandrogens (Fig. 1), suggesting that the
increased AR copy number did not predict androgen
insensitivity. Furthermore, the mean AR copy number
after relapse was no higher than that seen in the primary
tumours (before therapy). Most strikingly, only three
patients had amplification of the AR gene after hormone
relapse; of these, one (5% of primary biopsies) had
amplification of the AR gene before antiandrogen
therapy. This patient, despite having the greatest ampli-
fication found in the study both in tumours before and
after relapse, had a full PSA response to antiandrogen
therapy. In this patient the PSA relapse could not
be related to increased gene amplification of the AR
(Fig. 1b).
These results, in which neither increased AR copy
number nor amplification preclude a response to anti-
androgen therapies, and where relapse is clearly not
associated with either increased copy number or ampli-
fication of AR, call into question the role of alterations
in AR copy number in hormone relapse in prostate
cancer.
Although an increase in AR gene copy number does
not seem to explain the development of hormone-
refractory prostate cancer, we cannot, at present, exclude
a change in the level of AR protein expression. Increases
in AR expression may lead to hormone resistance and
studies are currently underway to address this aspect of
AR function in these samples. More recently it has been
suggested that the development of hormone-resistant
prostate cancer need not involve increased levels of AR
but may involve mechanisms which alter AR function
with no changes in expression. Recent evidence shows
that activation of protein kinase A can up-regulate
the expression of androgen-regulated genes via the
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Fig. 1. a, The PSA profile for patient no. 1, showing elevated PSA
levels at diagnosis, which reduced in response to treatment and
increased when androgen-deprivation therapy failed. This patient,
who initially responded to androgen-deprivation therapy, had no
abnormalities in biopsies either before or after relapse for
X chromosome or AR copy numbers. b, The PSA profile for patient
no. 7, showing a sharp increase in PSA levels at relapse. There
was no available value for PSA at diagnosis, but the records showed
that PSA was elevated during this period. This patient responded
to androgen-deprivation therapy and had AR amplification in
biopsies both before and after relapse. c, The PSA profile for patient
no. 20, showing high PSA levels at diagnosis, which increased until
treatment was given and then decreased until relapse. This patient
responded to androgen-deprivation therapy and had AR amplifica-
tion only in the biopsy taken after relapse. In all figures the data-
points shown as green circles are the mean AR copy number in each
biopsy and those shown as red squares the PSA profile.
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transcription factors cyclic AMP binding protein and
activation transcription factor, by androgen-independent
activation of AR [14,15] or via pathways that do not
involve AR [16]. The protein kinase C pathway has also
been reported to stimulate the expression of androgen-
regulated genes via AP-1, an AR-independent signal
transduction pathway [16,17]. Activation of either of
these pathways would stimulate prostate tumour growth
in the absence of circulating androgens, but whether any
of these pathways are involved in androgen escape
remains to be determined.
A lack of understanding of the mechanisms driving
antiandrogen escape in prostate cancer remains central
to the failure to develop viable alternative therapies for
patients with hormone-relapsed disease. By investigating
paired tumour samples before and after hormone relapse
we provide evidence that questions the role of AR
amplification in the process of hormone escape. As
discussed above, alternative pathways may need to be
investigated and could provide novel therapeutic targets
for this important disease.
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